Entrada Therapeutics Statistics
Total Valuation
TRDA has a market cap or net worth of $655.18 million. The enterprise value is $219.97 million.
Important Dates
The next confirmed earnings date is Tuesday, November 5, 2024, before market open.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TRDA has 35.19 million shares outstanding. The number of shares has increased by 9.14% in one year.
| Current Share Class | 35.19M |
| Shares Outstanding | 35.19M |
| Shares Change (YoY) | +9.14% |
| Shares Change (QoQ) | +14.43% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 51.40% |
| Float | 18.20M |
Valuation Ratios
The trailing PE ratio is 12.01.
| PE Ratio | 12.01 |
| Forward PE | n/a |
| PS Ratio | 2.93 |
| Forward PS | 10.85 |
| PB Ratio | 1.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 4.00 |
| EV / Sales | 1.02 |
| EV / EBITDA | 3.59 |
| EV / EBIT | 3.81 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.59, with a Debt / Equity ratio of 0.15.
| Current Ratio | 6.59 |
| Quick Ratio | 6.40 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 16.43% and return on invested capital (ROIC) is 9.03%.
| Return on Equity (ROE) | 16.43% |
| Return on Assets (ROA) | 6.95% |
| Return on Capital (ROIC) | 9.03% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | $345,604 |
| Employee Count | 159 |
| Asset Turnover | 0.41 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TRDA has paid $21.47 million in taxes.
| Income Tax | 21.47M |
| Effective Tax Rate | 28.09% |
Stock Price Statistics
The stock price has increased by +11.83% in the last 52 weeks. The beta is -0.27, so TRDA's price volatility has been lower than the market average.
| Beta (5Y) | -0.27 |
| 52-Week Price Change | +11.83% |
| 50-Day Moving Average | 16.26 |
| 200-Day Moving Average | 14.97 |
| Relative Strength Index (RSI) | 68.97 |
| Average Volume (20 Days) | 105,221 |
Short Selling Information
The latest short interest is 1.65 million, so 4.70% of the outstanding shares have been sold short.
| Short Interest | 1.65M |
| Short Previous Month | 2.04M |
| Short % of Shares Out | 4.70% |
| Short % of Float | 9.09% |
| Short Ratio (days to cover) | 9.56 |
Income Statement
In the last 12 months, TRDA had revenue of $215.23 million and earned $54.95 million in profits. Earnings per share was $1.55.
| Revenue | 215.23M |
| Gross Profit | 115.35M |
| Operating Income | 57.78M |
| Pretax Income | 40.51M |
| Net Income | 54.95M |
| EBITDA | 61.30M |
| EBIT | 57.78M |
| Earnings Per Share (EPS) | $1.55 |
Full Income StatementBalance Sheet
The company has $449.34 million in cash and $61.31 million in debt, giving a net cash position of $388.03 million or $11.03 per share.
| Cash & Cash Equivalents | 449.34M |
| Total Debt | 61.31M |
| Net Cash | 388.03M |
| Net Cash Per Share | $11.03 |
| Equity (Book Value) | 422.45M |
| Book Value Per Share | 11.30 |
| Working Capital | 394.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.97 million and capital expenditures -$3.50 million, giving a free cash flow of -$17.46 million.
| Operating Cash Flow | -13.97M |
| Capital Expenditures | -3.50M |
| Free Cash Flow | -17.46M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
Gross margin is 53.59%, with operating and profit margins of 26.85% and 25.53%.
| Gross Margin | 53.59% |
| Operating Margin | 26.85% |
| Pretax Margin | 35.51% |
| Profit Margin | 25.53% |
| EBITDA Margin | 28.48% |
| EBIT Margin | 26.85% |
| FCF Margin | -57.65% |